Krown Susan E
Melanoma Sarcoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):395-402. doi: 10.1016/j.cytogfr.2007.06.005. Epub 2007 Jul 25.
Interferon alfa (IFNalpha) was one of the first agents to be used therapeutically in AIDS-associated Kaposi's sarcoma (KS) more than 25 years ago, and induces tumor regression in a subset of patients. Although much has been learned about the clinical role of IFNalpha in KS treatment, little is currently known about the mechanism(s) by which IFNalpha causes KS regression. This is despite a growing understanding of both KS pathogenesis and relevant IFNalpha activities. To a large extent other agents have supplanted IFNalpha as treatments for KS, but there may still remain a therapeutic role for IFNalpha, possibly in combination with other agents targeting angiogenesis and/or HHV-8-encoded human gene homologs that encode proteins involved in cell cycle regulation and signaling.
25多年前，干扰素α（IFNα）是最早用于治疗艾滋病相关卡波西肉瘤（KS）的药物之一，可使部分患者的肿瘤消退。尽管人们对IFNα在KS治疗中的临床作用已有很多了解，但目前对IFNα导致KS消退的机制知之甚少。尽管对KS发病机制和相关IFNα活性的认识不断增加，但情况依然如此。在很大程度上，其他药物已取代IFNα用于KS治疗，但IFNα可能仍具有治疗作用，可能与其他靶向血管生成和/或编码参与细胞周期调控和信号传导蛋白质的HHV-8编码人类基因同源物的药物联合使用。
